chrisvoncsefalvay/vaers-outcomes huggingface dataset:
VACCINE WAS STORED PAST RECOMMENDED STORAGE CONDITIONS AFTER PUNCTURE; 1 DOSE OF VACCINE THAT WAS STORED PAST RECOMMENDED STORAGE CONDITIONS ADMINISTERED; OFF LABEL USE; This spontaneous report received from a health care professional concerned a 60 year old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine (suspension for injection, route of admin not reported, batch number: 207A21A and expiry: UNKNOWN) dose was not reported, administered on 21-SEP-2021 for prophylactic vaccination. No concomitant medications were reported.  On 21-SEP-2021, the patient experienced vaccine was stored past recommended storage conditions after puncture. On 21-SEP-2021, the patient experienced 1 dose of vaccine that was stored past recommended storage conditions administered. On 21-SEP-2021, the patient experienced off label use. The action taken with covid-19 vaccine was not applicable. The outcome of the vaccine was stored past recommended storage conditions after puncture, 1 dose of vaccine that was stored past recommended storage conditions administered and off label use was not reported. This report was non-serious.
Headache every single day since the second dose of the covid vaccine in April, 2021. Cough and/or shortness of breath every day since second dose in April, 2021
symptoms of an allergic reaction to the shot; This case was reported by a consumer via call center representative and described the occurrence of allergic reaction in a 67-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th February 2020, the patient received Shingrix. In February 2020, less than a week after receiving Shingrix, the patient experienced allergic reaction. On an unknown date, the outcome of the allergic reaction was unknown.   It was unknown if the reporter considered the allergic reaction to be related to Shingrix.  Additional details were provided as follows: The age at vaccination not provided but it could be 66 or 67 years. The pateint had symptoms of an allergic reaction after taking shot of Shingrix.
Whole shoulder swollen and red, very weak, headache, nausea, achy joints and muscles.
Temperature; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. On an unknown date the patient experienced temperature. The clinical outcome of the event temperature was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Arm had initial swelling and pain for 3 days post injection.  Then completely healed until day 8, when I woke up with a large, hot, itchy raised lump at the injection site.  By day 9 it was the size of an egg and continued to be very hot, raised and itchy.  Day 10 the lump is less pronounced but the diameter of the initial welt has grown to approximately 3".  It is still hot and itchy but less hard feeling today.
Husband started with nose bleed 20 minutes after receiving 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of EPISTAXIS (Husband started with nose bleed 20 minutes after receiving 1st dose) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Patient's medical history included No Adverse event.  Concomitant products included ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced EPISTAXIS (Husband started with nose bleed 20 minutes after receiving 1st dose). At the time of the report, EPISTAXIS (Husband started with nose bleed 20 minutes after receiving 1st dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Other concomitant medications included Blood thinner  No treatment information was provided.
At about 26 hours after immunization, patient had severe nausea and headache. This was followed up by soreness throughout her body and arthritis type pain in her joints. A few hours later her arm had begun to swell and the injection site swelled and became bright red. This swelling went up her arm and into her neck on the left side. Her lymph nodes became swollen. Two days after injection, she developed an itch throughout her body that persisted for 24 hours and she became lethargic.
Significant swelling and pain in the area surrounding the injection, limiting ability to raise the arm, persisting for at least 6 days and continuing despite administration of Acetaminophen and application of ice to swelled area.
arm  red; Itching all over; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 14-Jun-2021 and was forwarded to Moderna on 14-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (arm  red) and PRURITUS (Itching all over) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (arm  red) and PRURITUS (Itching all over). At the time of the report, ERYTHEMA (arm  red) and PRURITUS (Itching all over) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.   No treatment information was provided.
Right anterior upper arm with swelling, redness, warm to touch causing discomfort.  Area swollen to approximately twice its normal size. Encouraged elevation for swelling and discomfort. OTC Benadryl PRN
Patient received dose of monovalent Pfizer after 4/18 when the FDA stopped use of the monovalent vaccines.    Patient has upcoming appt on 7/11/23 and BIVALENT dose will be offered at that time.
became ill on Friday 100/am /w T 103, crying vomiting. Took to ER
The patient presented to our clinic with a Date of Birth of 7/30/2008.  The patient was new in our system.  The patient presented with the parent and did not provide insurance card.  Received a call from our state registry that the patient was too young to be vaccinated.  These vaccines were interfaced over into the patients chart in WIR, however the Date of Birth listed was 7/30/2009 (in WIR). From our knowledge the patient did not have any adverse outcomes.  It appears the parent provided the incorrect DOB when they registered for a MyChart account to set up an appointment for the vaccine.  So according to the information provided, the patient was at the approved age, but information is pointing toward the patient was actually 11.
Headache, Myalgia, Arthralgia, soreness left arm Narrative:
Case number PHEH2017US005404, is an initial spontaneous report received from a nurse on 17 Feb 2017. This report refers to a female patient of an unknown age. Past medical history and concomitant medications were not reported. The patient was vaccinated with FLUVIRIN (seasonal, batch number: not reported) at a dose of 0.5 ml on an unknown date in Sep 2016 subcutaneously. On an unknown date after vaccination, the patient developed red, raised rash from elbow to under arm of injection site. It was also reported that, the injection was given in a different physician office and nurse believed it might had been given subcutaneously instead of intramuscularly. The patient fully recovered from vaccination site rash, rash popular and rash erythematous on an unknown date. These events vaccination site rash, rash erythematous and rash papular were considered non-serious by the nurse. The causality of he events was not reported.
Doctor ordered HIB, HEP A & Varicella. An adult dose of HEP A was given by mistake. Spoke to GSK, they said soreness at injection site & malaise would be side effects. Dr spoke to mother of pt. All was documented in EMR - incident report was completed & submitted to our compliance dept.
Pt c/o lightheadness post vaccine administration. Experienced a syncopal episode. No trauma, witnessed event. Examined pt and no abnormal findings. Pt states this has happened before with previous vaccines. Observed and stable. BP taken was 108/70. HR 79, spO2 97%, RR 14.
Patient stated that she had an all-over-body rash after receiving a booster dose of MCV4, but denies other symptoms. Patient called triage nurse at the medical clinic and was sent to ER for evaluation. Note: this was a booster dose of MCV4, but patient previously received Menactra. Patient received Menveo at this visit.
7+ days of redness, swelling, heat over the injection site. By day 3 localized reaction spread to a raised hot, painful rash approx 4x5 inches; 7+ days of redness, swelling, heat over the injection site. By day 3 localized reaction spread to a raised hot, painful rash approx 4x5 inches; 7+ days of redness, swelling, heat over the injection site. By day 3 localized reaction spread to a raised hot, painful rash approx 4x5 inches; 7+ days of redness, swelling, heat over the injection site. By day 3 localized reaction spread to a raised hot, painful rash approx 4x5 inches.; This is a spontaneous report from a contactable Nurse (patient herself). This 44-year-female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection) via an unspecified route of administration Left arm on 12Feb2021 13:30 as single dose for COVID-19 immunisation. Medical history included Polycystic, Depression, Deep vein thrombosis and Pulmonary Embolism. Concomitant medications included Levothyroxine, escitalopram oxalate (LEXAPRO), ASA, ibuprofen, apap. Patient historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection) via an unspecified route of administration in Left arm on 22Jan2021 for COVID-19 immunization. On 15Feb2021 patient experienced with 7+ days of redness, swelling, heat over the injection site, localized reaction spread to a raised hot, painful rash approx 4x5 inches. Patient did not receive any treatment for the events. Outcome of events was recovering.  Lot/Batch number has been requested.
Muscles aches; Her arm is hurting; This is a spontaneous report received from a contactable reporter(s) (Physician) from medical information team, Program ID. The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), on 08Jan2021 as dose 1, single (Lot number: EL3246) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset Jan2021, outcome "not recovered", described as "Her arm is hurting"; MYALGIA (non-serious) with onset Jan2021, outcome "unknown", described as "Muscles aches".  Additional Information: Reporter mentioned that she had the Pfizer COVID-19 vaccine and she experienced some side effects and she was inquiring about the side effects of the vaccine. After her first dose she experienced the usual muscles aches and all, her arm was hurting which she was not concerned about.
42 YO received Shingrix; Felt sick; This non-serious case was reported by a consumer and described the occurrence of sickness in a 42-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In APR-2023, the patient received Shingrix. In APR-2023, an unknown time after receiving Shingrix, the patient experienced inappropriate age at vaccine administration (Verbatim: 42 YO received Shingrix). On an unknown date, the patient experienced sickness (Verbatim: Felt sick). The outcome of the sickness was resolved (duration 2 days) and the outcome of the inappropriate age at vaccine administration was unknown.   It was unknown if the reporter considered the sickness to be related to Shingrix.     It was unknown if the company considered the sickness to be related to Shingrix.   Additional Information: GSK receipt date:04-May-2023 This case was reported via companies. The patient felt sick for 2 days after vaccination. The reporter consented to follow up.
p/vax pt became apneic; to ER; mom stated stopped breathing between 10-20 seconds; monitored;no apnea noted in hosp;
no adverse event; multiple patients were vaccinated with an improperly stored vaccine; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported.  On 21-MAY-2019, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ), 2 ml, orally, lot # R034700, expiry date 16-JUN-2020 for prophylaxis. The vaccine was exposed to a temperature of 34.2 Fahrenheit degrees for 4 hours and 54 minutes. Digital data logger was involved. There were no previous temperature excursions. No adverse effects were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  1907USA000925:Original Case : 1907USA000862 US-009507513-1906USA011674: US-009507513-1907USA000883: US-009507513-1907USA000884: US-009507513-1907USA000885: US-009507513-1907USA000926: US-009507513-1907USA000927: US-009507513-1907USA000886: US-009507513-1907USA000887: US-009507513-1907USA000888: US-009507513-1907USA000928: US-009507513-1907USA000930: US-009507513-1907USA000931: US-009507513-1907USA000932: US-009507513-1907USA000889: US-009507513-1907USA000890: US-009507513-1907USA000891: US-009507513-1907USA000892: US-009507513-1907USA000933: US-009507513-1907USA000934: US-009507513-1907USA000935: US-009507513-1907USA000893: US-009507513-1907USA000894: US-009507513-1907USA000895: US-009507513-1907USA000929: US-009507513-1907USA000936: US-009507513-1907USA000937: US-009507513-1907USA000938: US-009507513-1907USA000896: US-009507513-1907USA000897: US-009507513-1907USA000898: US-009507513-1907USA000899: US-009507513-1907USA000900: US-009507513-1907USA000901: US-009507513-1907USA000902: US-009507513-1907USA000903: US-009507513-1907USA000904: US-009507513-1907USA000905: US-009507513-1907USA000862: US-009507513-1907USA000907: US-009507513-1907USA000908: US-009507513-1907USA000909: US-009507513-1907USA000910: US-009507513-1907USA000911: US-009507513-1907USA000912: US-009507513-1907USA000913: US-009507513-1907USA000914: US-009507513-1907USA000915: US-009507513-1907USA000916: US-009507513-1907USA000917: US-009507513-1907USA000918: US-009507513-1907USA000919: US-009507513-1907USA000920: US-009507513-1907USA000921: US-009507513-1907USA000922: US-009507513-1907USA000882: US-009507513-1907USA000923: US-009507513-1907USA000924: US-009507513-1907USA000925:
Pt called to report.."a reaction I had to the Pneumonia shot I had yesterday".  Received injection at 1300 3/10/08 and said by 1500 she was having left arm pain that worsened and limited ROM.  Also local redness and edema reported as size of bean.  Also C/O fatigue and body aches  No reported fever...  Said she feels better today, arm less sore and red...
Patient had the flue at least once and sometimes twice a year; Initial information received on 08-Dec-2020 regarding this unsolicited valid non-serious social media case from a consumer (patient).    This case involved 80 years old patient with unknown gender who had the flue at least once and sometimes twice a year (influenza), while the patient received INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.    On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via an unknown route at an unknown administration site.    On an unknown date, the patient had the flue at least once and sometimes twice a year (influenza) (Unknown latency) following the administration of INFLUENZA VACCINE.  Patient had not taken it for 12 years and had not had flu for 12 years.  Details of laboratory data was not reported.  It was not reported if the patient received a corrective treatment.  The event outcome was reported as unknown for the event, at the time of reporting.  There will be no information available on the batch number for this case.
BODY ACHES; DIFFICULTY FOCUSING / CONCENTRATING; GENERAL MALAISE; EXTREME FATIGUE; 101.5 FEVER; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 2021 for prophylactic vaccination. The batch number was not reported has been requested. No concomitant medications were reported.  On 2021, the subject experienced body aches. On 2021, the subject experienced difficulty focusing / concentrating. On 2021, the subject experienced general malaise. On 2021, the subject experienced extreme fatigue. On 2021, the subject experienced 101.5 fever.  Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 101.5. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the 101.5 fever, body aches, general malaise, extreme fatigue and difficulty focusing / concentrating was not reported. This report was non-serious.
Client, who is a PA, reports severe gallbladder pain. that started about noon the day after vaccinated. He went to Urgent Care and examined by coworker, received Tordol IM, and had labs drawn which were WNL. He was diagnosed with gallbladder pain.The pain resolved after 5-6 hours.
Hospitalized 7/29/22-8/2/22 cough, fever, aspiration at intubation 7/27/22, SOB, body aches, tachypnea, PNA, hypoxia, anemia,
The adverse event is the administration of 2 doses of varicella.  One dose as varicella and the second dose as an MMRV vaccine.
Information has been received from a physician concerning a 19 year old female with no persistent medical history or drug reactions/allergies, who on 15-Dec-2006 was vaccinated with Gardasil vaccine (yeast) (0.5 ml). There was no concomitant medication. On 15-Dec-2006, following vaccination, the patient developed a red itchy rash "all over". Unspecified medication attention was sought. At the time of this report the patient had not recovered. No additional information is available.
mom reported pt had t102 for 2 days; by the 3rd day pt was listless for about 24 hrs; devel a rash on 5th day;
No adverse effects; An expired dose of PROQUAD that had no previous temperature excursions, was inadvertently administered to an unspecified patient; This spontaneous report as received from a registered nurse referring to a 5 year old male patient. The patient's concurrent condition included seasonal allergies. The patient was previously vaccinated with measles virus vaccine live (Enders-Edmonston) (+) mumps virus v (M-M-R) and varicella virus vaccine live (Oka/Merck) (VARIVAX). On 09-MAY-2017 09:15 the patient was inadvertently vaccinated with expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) Human serum albumin (HSA)(lot # L024497, expiry date : 01-JAN-2017), for prophylaxis (expired product administered). On 09-MAY-2017 09:15, the patient was vaccinated with dose 5 of diphtheria toxoid, pertussis acellular 5-component vaccine, tetanus toxoid(DAPTACEL) from lot C5117AA intramuscular in the right arm and dose 4 of poliovirus vaccine inactivated (vero)(IPOL) from lot L024497 subcutaneous in the right arm; for prophylaxis. Concomitant therapies included sterile diluent(Manufacturer Unknown) (Lot# and expiration date was unknown by the reporter). There was no previous temperature excursions. No adverse effects reported. There was no product quality complaint involved.  This is one of the several reports linked via same reporter link.
Broke out in hives on 2nd day after 2nd shot.  Today is the 10th day, rash is less, but still active.
This spontaneous report as received from a health department nurse refers to an unknown number of patients of unknown ages and genders. On unknown dates the patients were vaccinated with VARIVAX injection which underwent a supported temperature excursion, but was outside the recommended temperature provided in the prescribing information, intramuscular for vaccination (lot #, expiry date and dose unknown). No adverse effects reported. Follow up information has been received on 02-APR-2014. A phone call was placed to Registered Nurse. The Program Manager stated that nurse was unavailable at that time, but the VARIVAX underwent a supported temperature excursion (and administered in 2014). On 17-FEB-2014, lot number: J009731, expiration date: 7-AUG-2015, 70 doses were shipped and 70 doses were in the freezer at the time of discovery. Patient identifiers were not available at this time. No further information is available at this time. This is one of several reports from the same source. Additional information has been requested.
At night he had dizziness, muscle pain and very sleepy. He had no appetite for 3 days.
Patient had a MMR vaccine. Twenty minutes after vaccine, patient had erythematous(macular) flushing on face, back, legs with erythema and induration around injection site. He was given EPI SG1:1000 .1cc at 155pm and Benadry 12.5mg 1M 2pm. During period of observation, there was no wheezing, however patient had a small amount of upper airway noise. Vital signs remained stable throughout and patients lips were pink. Because of mild upper airway noise, patient was transferred via ambulance to ER. By the time that he arrived there, he was asymptomatic from a respiratory standpoint. He was observed, given Prelone orally, and sent home. He took Prelone for 3 days total. He was seen in office on 12/6/02 with a normal examination.
body felt cold; Tiredness; This is a spontaneous report from a contactable consumer, a patient and other healthcare professional. A 50-year-old Male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EL3247), via an unspecified route of administration in the right arm on 11Mar2021 at 1300 hours (at the age of 50-years-old), as a first single dose for COVID-19 immunisation. Concomitant medications included Zyrtec and multi vitamins (manufacturer unknown), for an unspecified indication. The patient did not have any allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 12Mar2021 the patient experienced tiredness and on 16MAR2021, the patient's body felt cold, however patient did not have any fever and was able to maintain his normal schedule of work and exercise. The clinical outcome of the event tiredness was recovering. The clinical outcome of the event felt cold was unknown. No follow-up attempts are possible. No further information is expected.